Prevalence of Cognitive Disorders in Newly Diagnosed Epilepsy (PRECONISE)
A prospective prevalence study recorded that up to 50% of adult patients with newly diagnosed epilepsy had at least one cognitive impairment before initiation of antiepileptic drug (AED). Multiple factors exist and interact in the same patient. Cognitive impairments may affect psychiatric (loss of self-esteem, anxiety, depression) and social status (e.g., vocational aptitude, educational). These factors in turn influence cognitive abilities in a triangular and bidirectional relationship. In addition, the type of epilepsy, development in childhood or cerebral ageing, antiepileptic treatments (AED, surgery) and etiology also have an impact on cognitive performances. The burden of these factors differs from patient to another and must be determined individually. Longitudinal follow-up seems to be crucial because it will allow us to highlight the change in the cognitive profile of newly diagnosed patients over time.
The main objective is to compare the prevalence of cognitive impairment in patients with newly diagnosed epilepsy prior to the initiation of AED with healthy subjects matched on age, sex, manual laterality and socio-educational level. But also to compare the longitudinal evolution of the cognitive profile of patients with healthy controls (0 to 10 years) to determine, among the age of onset seizures, their etiology, the syndrome, the sex, the socio-educational level and the cognitive reserve, which one are related to the severity of cognitive disorders.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Natacha Forthoffer
- Numero di telefono: 03.83.85.20.77
- Email: n.forthoffer@chru-nancy.fr
Luoghi di studio
-
-
-
Nancy, Francia, 54000
- Reclutamento
- Department of neurology - Hospital of Nancy
-
Contatto:
- Forthoffer Natacha
- Email: n.forthoffer@chru-nancy.fr
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria (patients):
- Individuals who have received full information about the organization of the research and have not refused to participate and to use their data.
- Person aged 16 and over
- For minor patients: the non-opposition of the parental authority holders
- Newly diagnosed epileptic patient who had never taken antiepileptic drugs.
Inclusion Criteria (normal controls):
- Individuals who have received full information about the organization of the research and have not refused to participate and to use their data.
- For minor participants: the non-opposition of the parental authority holders
- Person aged 16 and over.
Exclusion Criteria (patients):
- Person of full age who are subject to a legal protection measure or who are unable to express their consent
- Person with a progressive brain injury
- Person who regularly use psychoactive substances (cannabis, alcohol, etc.)
- Patients who started an antiepileptic treatment before the neuropsychological assessment.
Exclusion Criteria (normal controls):
- Persons of full age who are subject to a legal protection measure or who are unable to express their consent
- Person with a neurological (traumatic brain injury, stroke, etc.) and/or psychiatric (mental illness, depression, etc.) history.
- People who regularly use psychoactive substances (cannabis, alcohol, etc.).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Newly diagnosed epileptic patients
Newly diagnosed epileptic patients who have never be treated by antiepileptic drugs and who have no psychiatric (mental illness) and/or evolutive neurological history and for minor patients the non-opposition of the parental authority holders.
|
Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests.
There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
|
|
Normal controls
Matched (on age, gender, socio-educationnal level and manual laterality) healthy controls who have no psychiatric (depression, mental illness) and/or neurological (stroke, traumatic brain injury, etc.) history and for minor patients the non-opposition of the parental authority holders.
|
Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests.
There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The percentage of impaired cognitive function at the time of diagnosis in patients and healthy subjects.
Lasso di tempo: Baseline (up to 2 weeks after a diagnosis of epilepsy for a duration of 1h30)
|
Neuropsychological assessment:
Questionnaires:
|
Baseline (up to 2 weeks after a diagnosis of epilepsy for a duration of 1h30)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of impaired cognitive functions according to the cognitive domain assessed
Lasso di tempo: Baseline, 6 months, 12 months, 3 years, 6 years and 10 years after the baseline (for a duration of 1h30 at each assessment)
|
Participants are assessed 6 times Neuropsychological assessment:
Questionnaires:
|
Baseline, 6 months, 12 months, 3 years, 6 years and 10 years after the baseline (for a duration of 1h30 at each assessment)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Louis Maillard, Pr, Professor of Neurology
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- n°2020-A00404-35
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .